PeerBridge Health

PeerBridge Health, founded in 2012 as Wireless Live Inc., is a New York-based digital health company focused on the remote cardiac monitoring market. The company's inception traces back to its founder, Dr. Angelo Acquista, a pulmonologist who was inspired by the challenges his father faced with traditional, cumbersome Holter monitors. This personal experience drove his mission to develop a more patient-friendly monitoring solution that provides high-quality health data. Dr. Acquista, a graduate of New York University School of Medicine, has a background in internal and pulmonary medicine and has served as a medical advisor for the NYC Mayor's Office of Emergency Management.

The company's core offering is an AI-driven platform centered around the Peerbridge Cor™, a wearable, wireless ambulatory ECG (AECG) patch. This 3-lead, 2-channel device received FDA 510(k) clearance in 2017. It is designed based on Einthoven's Triangle, a principle that helps it mirror the data capture of a 12-lead hospital-grade ECG. The Cor™ is water-resistant and can be worn for up to seven days, continuously recording heart activity to detect various arrhythmias. A key differentiator is its ability to provide clear P-wave definition and QRS morphology, allowing for more precise diagnoses. Clinical trials have demonstrated its superiority when compared side-by-side with traditional Holter monitors.

PeerBridge Health operates on a business-to-business model, serving healthcare providers, clinics, and hospitals. These clients utilize the Peerbridge Cor™ system for remote patient monitoring, which includes the wearable sensor and a cloud-based data management platform for physician analysis. The platform's AI capabilities are expanding to include diagnostics for conditions like heart failure, ejection fraction, and sleep apnea, often requiring as little as five minutes of wear time for an initial assessment. For example, a 2023 feasibility trial showed the platform could determine the presence of heart failure with 95.7% accuracy. The company is actively pursuing further FDA clearances to broaden its diagnostic applications, including a pivotal trial for sleep apnea detection. Having raised a total of $59M over 13 funding rounds, with the latest being a Series C round in June 2024, the company is capitalized for growth and continued development.

Keywords: remote cardiac monitoring, wearable ECG, ambulatory ECG, arrhythmia detection, digital health, AI diagnostics, heart failure detection, remote patient monitoring, Holter monitor replacement, electrocardiogram patch, cardiovascular monitoring, medical device, P-wave analysis, QRS morphology, sleep apnea detection, ejection fraction estimation, wireless health, MedTech, continuous monitoring, vital signs monitoring, cardiac diagnostics, healthcare technology